MDM2i elicit a p53 response in all models of ER+ breast cancer tested that are TP53 wild type, giving the expected outcomes of apoptosis, senescence, and cell cycle arrest, although relative levels of apoptosis are lower than in some other tumour types. This evidence concerns the gene TP53 and breast carcinoma.